An interventional study of tDCS and Action Observation Therapy (AOT) in Stroke, tDCS and Action Observation Therapy, sponsored by Universiti Malaysia Sabah. Recruiting at 2 sites in Malaysia. Open to participants aged 18 Years to 59 Years. Per ClinicalTrials.gov, last updated 2026-05-12.
Sponsored by Universiti Malaysia Sabah · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Stroke with a site in Malaysia — 6 open to participants now, 8 under way, 2 of them phase 3. Stroke · Malaysia.
Among the 45 studies in Stroke with a site in Malaysia, this one is the 29th largest by planned enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2026, is one of 18 with no phase, and was the 41st registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →6 of the 45 studies in Stroke with a site in Malaysia are open now. Recruiting first, the newest first:
National University of Malaysia · Sites in Malaysia
Ages 18–80
Eli Lilly and Company · Sites in Malaysia, Argentina, Australia and 35 more countries
Ages 50+
Region Skane · Sites in Malaysia, United States, Australia and 5 more countries
Ages 18+
Hospital Pengajar Universiti Putra Malaysia · Sites in Malaysia
Ages 50+
University of Malaya · Sites in Malaysia
Ages up to 75
A study can be open while its sites in Malaysia have not opened yet or have stopped. Only those recruiting at a site in Malaysia →
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years to 59 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 13 · Phase 4 4
First in 1998; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 345 across the 40 interventional studies, 2,297 across the 5 observational. Of the 33 that completed or were terminated, 11 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 45 have an industry lead sponsor. The 10 most frequent:
Universiti Malaysia Sabah is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
Universiti Malaysia Sabah has 1 study filed under Stroke — fewer than ten, so there is no comparison to draw.
4 of the studies in Stroke with a site in Malaysia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07400939Universiti Malaysia SabahBrain Stimulation Combined With Watching Hand Movements to Improve Hand Recovery in Chronic Stroke | 2027-01-20 |
| NCT06429332Region SkaneInternational Care Bundle Evaluation in Cerebral Hemorrhage Research | 2027-03-01 |
| NCT07522463University of MalayaEnhancing Attention and Processing Speed Through Home-based Music Rehabilitation Program After Stroke in Malaysia | 2027-06-30 |
| NCT05082467Sarawak General HospitalProlonged Cardiac ECG Patch Versus Conventional Holter For Detecting Atrial Fibrillation After Cerebral Ischemic Event | 2027-08-22 |
Add all 4 to your calendar (.ics) → With an account.
Among the 45 studies in Stroke with a site in Malaysia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study investigates the neurophysiological mechanisms underlying the combined use of transcranial direct current stimulation (tDCS) and action observation therapy (AOT) for hand motor recovery in individuals with stroke. Background: While both tDCS and AOT have shown promise individually for stroke rehabilitation, the neural mechanisms of their combined effects remain unclear. Understanding these mechanisms could optimise rehabilitation protocols and improve functional outcomes. Intervention: Participants will receive 10 sessions of anodal tDCS over the ipsilesional motor cortex combined with AOT over two weeks in a clinical setting, followed by 8 weeks of home-based AOT practice. Control groups will receive tDCS alone or AOT alone. Neurophysiological changes will be assessed using motor evoked potentials (MEPs) to evaluate corticospinal excitability. Clinical hand function will be assessed using standardised outcome measures. Measurements: Assessments will be conducted at baseline, during intervention (week 2), and after the home practice phase (week 10) to evaluate neuroplastic changes. Significance: This study will provide mechanistic insights into how neuromodulation and observational learning interact to promote motor recovery, informing evidence-based rehabilitation strategies for stroke survivors in Malaysia and globally. Study Design: Randomised controlled trial with three parallel arms, recruiting 60 participants with chronic stroke from Sabah, Malaysia.
The participation duration for each participant is 10 weeks, including the assessment period.
Group 1 tDCS + AOT (intervention): tDCS will be administered at the outpatient clinic for 20 minutes per session, for a total of 10 sessions over two consecutive weeks. During the tDCS sessions, each participant will engage in AOT for 30 minutes under the supervision of a therapist. Subsequently, each participant will continue performing AOT at home for 30 minutes per session, once a day, five days per week, for 8 consecutive weeks.
Group 2 tDCS alone (control): tDCS will be administered at the outpatient clinic for 20 minutes per session, for a total of 10 sessions over two consecutive weeks. During the tDCS sessions, each participant will watch a landscape video for 30 minutes. Subsequently, each patient will continue watching the landscape video at home for 30 minutes per session, once a day, five days per week, for 8 consecutive weeks.
Group 3 AOT alone (control): placebo tDCS will be administered at the outpatient clinic for 20 minutes per session, for a total of 10 sessions over 2 consecutive weeks. During the placebo tDCS sessions, each participant will engage in AOT for 30 minutes under the supervision of a therapist. Following the clinic sessions, each patient will continue performing AOT at home for 30 minutes per session, once a day, five days per week, for 8 consecutive weeks.
The principal investigator will visit each research site throughout the duration of the study. All participants will attend the outpatient rehabilitation setting five times a week for 30 minutes per session, for 2 consecutive weeks, and continue intervention at home for five days a week for 8 consecutive weeks. The total intervention duration consists of 10 consecutive weeks. For each session in the hospital, there will be a physiotherapist to monitor participants' compliance with the interventions and to ensure that the training is conducted as per protocol. Level of participation would be measured by Rating of Perceived Exertion Scale of 3-5 (light activity to somewhat hard). If the subject attended the session but refuse to participate in the intervention, the subject would be excluded from the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive anodal transcranial direct current stimulation (tDCS) at 2 mA for 20 minutes combined with action observation therapy (AOT) for 10 sessions over 2 weeks at an outpatient clinic. During tDCS delivery, participants will observe first-person perspective videos of hand motor tasks and practice the observed movements. Following the clinic phase, participants will continue AOT practice at home for 30 minutes once daily for 8 weeks.
Other: tDCS · Other: Action Observation Therapy (AOT)
Sham tDCS group - apply sham anodal tDCS with a 30s ramp-up and 30s ramp-down, switching the current to 0mA without the participant's awareness. Administer sham anodal tDCS for 20 minutes. Concurrently perform AOT for 30 minutes.
Other: Action Observation Therapy (AOT)
Administer active anodal tDCS for 20 minutes. Concurrently perform upper limb motor task actions with landscape video for 30 minutes.
Other: tDCS
* Stimulation type: Anodal stimulation * Electrode size: 5x7cm * Stimulation target: C3/C4 primary motor cortex (M1) based on the 10-20 international electroencephalography system * Stimulation intensity: 2 mA * Stimulation current density: 0.029-0.057 mA/cm2 Use tDCS with two saline-soaked surface sponge electrodes (5x7cm) applied to the scalp, secured with a headband. Stimulation intensity is set to 2mA, with 30s ramping up at the start and 30s ramping down at the end of stimulation.
Participants watch selected videos based on muscle grading of triceps, which include functional movement patterns and daily activity tasks of the upper limb. These videos are presented through a computer or mobile screen positioned at an appropriate distance from the participant to allow ample space for performing the required movements.
Motor Evoked Potentials (MEPs)
Peak-to-peak amplitude of motor evoked potentials (MEPs) elicited by single-pulse transcranial magnetic stimulation (TMS) and recorded via surface electromyography (EMG) from hand muscles of the paretic upper limb. Assessment Method: * TMS delivers single pulses over ipsilesional primary motor cortex (M1 hand area) * Surface EMG electrodes record responses from first dorsal interosseous (FDI), abductor pollicis brevis (APB), and extensor carpi radialis (ECR) muscles * Motor hotspot identified (optimal scalp location producing largest MEPs) * Resting motor threshold determined * 15-20 MEPs recorded at 120% of resting motor threshold * Inter-stimulus interval: 5-7 seconds * MEP amplitude measured as peak-to-peak voltage in millivolts (mV)
Time frame: From enrolment to the end of treatment at 10 weeks
Started Apr 2026 (actual). Primary completion is estimated for Jan 2027, 9 months after the start.
Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 9 months is below that.
Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universiti Malaysia Sabah